Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2019 April;67(2) > Minerva Cardioangiologica 2019 April;67(2):145-62

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Cardioangiologica 2019 April;67(2):145-62

DOI: 10.23736/S0026-4725.18.04686-8

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

New percutaneous interventions in heart failure

Elisabetta MOSCARELLA, Salvatore BRUGALETTA, Manel SABATÉ

Service of Cardiology, August Pi i Sunyer Institute for Biomedical Investigation (IDIBAPS), Clínic Hospital, Barcelona, Spain



Chronic heart failure (HF) is one of the main causes of mortality and morbidity worldwide and represents a growing challenge in interventional cardiology. Its prevalence is recently increasing due to the improvements in cardiac care with subsequent significant reduction in the HF acute mortality. HF may occur with either a reduced left ventricular ejection fraction (LVEF) (LVEF<40%, HFrEF) or a preserved EF (typically LVEF≥50%, HFpEF) indicative of diastolic dysfunction. Despite recent advances in drug therapies as well as in nonpharmacological strategies, including defibrillators, cardiac resynchronization therapy, LV assist devices, mortality in HF remains high. New transcatheter implantable devices have been developed to improve the treatment of chronic HF. In this review we will summarize data on interventional HF devices that are currently approved or under investigation including treatment alternatives for mitral and tricuspid regurgitation, LV restoration through partitioning devices and left atrial decompression with shunting devices.


KEY WORDS: Heart failure; Heart-assist devices; Percutaneous coronary intervention

top of page